The validity of the conclusion for primary glioblastoma, however, is questioned by the use of the IDH1 mutation as a marker for tumour cells since IDH1 mutations in glioblastoma confer to a genetically distinct and infrequent subset of glioblastoma, with better survival outcomes being predicted [43,44]. The gene discussed is IDH1; the disease is neoplasm.